Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/23/2012
Trade Name:
QNASL
Generic Name or Proper Name (*):
beclomethasone dipropionate
Indications Studied:
Treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis
Label Changes Summary:
Safety and effectiveness in children 12 years and older have been established Safety and effectiveness in <12 years have not been established Corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Routinely monitor the growth of pediatric patients receiving QNASL Nasal Aerosol The potential for QNASL Nasal Aerosol to cause reduction in growth velocity in susceptible patients or when given at higher than recommended dosages cannot be ruled out Information on safety, adverse events and clinical trials New dosage form
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Teva
Therapeutic Category:
Anti-inflammatory, topical
-
-